Reporter brief
METformin And Longevity (METAL): A Window of Opportunity Study Investigating Biological Effects of Metformin in Localised Prostate Cancer
What happened
Trial registry update: UNKNOWN. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- No findings are reported, so no clinical outcomes regarding metformin's effectiveness in prostate cancer can be assessed from this source
- The window of opportunity design (short-term intervention before standard treatment) limits generalizability to long-term use or effects on advanced disease
- Biological mechanism findings, if any exist, were not described in the provided abstract
Study design and sample
Rct; Human.
Patients with localised prostate cancer
- Design
- Rct
- Sample
- —
- Journal
- Guy's and St Thomas' NHS Foundation Trust
- Published
- Jul 30, 2015
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.